B

BioAge Labs

Clinical-stage biotech developing aging-targeted therapeutics

Translational AI Scientist/Engineer

AI Application EngineeringConfirmed live in the last 24 hours
Full-timeRemote in USA$150k - $185k

About the Job

Requirements

  • A PhD with 2 or more years of relevant experience, a master's degree with 5 or more years, or a bachelor's degree with 7 or more years in computer science, computational biology, biology, translation science, or a related field.
  • Hands-on experience building and deploying LLM-based agentic systems in production or production-like settings, including tool use, retrieval over structured and unstructured sources, multi-agent orchestration, structured outputs, provenance tracking, and cost and latency management.
  • Experience designing and running evaluations for AI systems, including reference sets, automated metrics, and regression testing, with understanding of interpretability and scientific reliability in decision-critical environments.
  • Strong software engineering fundamentals, including Python, testing, version control, API design, data modelling, and reproducible, auditable workflows such as orchestration, documentation, and continuous integration.
  • Experience integrating multimodal biological data, including omics, phenotype, perturbation, text, and literature, using AI-enabled or model-based approaches.
  • Experience with research AI system infrastructure, including relational and graph databases, cloud environments and containers, pipeline orchestration, and programmatic access to large public biological databases through APIs or bulk data.
  • Ability to distinguish absence of evidence from evidence against, report coverage alongside conclusions, and state evidence gaps rather than fill them plausibly.

Responsibilities

  • Design and deploy agentic AI systems that support scientific reasoning, hypothesis generation, and evidence synthesis for translational questions following target identification, including mechanism and source of signal, indication selection, experimental design, reagent quality, and translatability.
  • Build systems that recommend how to test a target, including experimental system, model, indication, endpoints tiered by translational relevance, intervention modality, and study parameters, grounding each choice in published precedent and explicitly stating when no precedent exists.
  • Develop tool-using workflows that retrieve and integrate structured and unstructured evidence, including knockout and perturbation phenotypes, endpoint precedent, published effect sizes, tool compound and reagent quality, prior programme outcomes, and primary literature, with full provenance.
  • Build the cross-species layer to determine whether a target's human signal is reproducible in a model system and identify readouts that link experimental results back to human cohort data.
  • Assess translatability by developing evidence that a human-derived signal will reproduce in vivo and onward, calibrating against targets with known preclinical and clinical outcomes, and feeding that evidence back into target prioritisation.
  • Build the systems' evaluation framework, including reference sets of targets with known experimental outcomes, metrics for citation quality and coverage, and calibration of translatability calls, with attention to scientific reliability and interpretability in decision-critical settings.
  • Encode domain rules about the meaning and reliability of each external source so absent, weak, and contradicting evidence are handled distinctly and never collapsed.
  • Partner with target biology and experimental teams so recommended designs are usable by the people running the studies, and incorporate study outcomes back into the system.
  • Own the systems end to end, including architecture, implementation, testing, deployment, and monitoring, as maintainable software scientists use day to day rather than one-off notebooks or prototypes.

Desired Qualifications

  • Hands-on or wet-lab research experience in one or more of in vivo pharmacology or disease models, target validation, disease biology, functional genomics, chemical biology, or translational science, sufficient to judge whether a proposed experiment or mechanism is sound.
  • Working knowledge of resources containing target and precedent evidence, including model organism phenotype databases, chemical probe and druggability resources, drug and clinical trial databases, pathway and perturbation resources, and the ability to judge their reliability.
  • Familiarity with evidence linking preclinical results to clinical outcomes, including genetic support and animal-to-human translation literature.
  • Ability to work effectively across scientific and engineering functions, with strong written and oral communication, self-motivation, and independence.
  • Background in aging biology or geroscience, including healthspan endpoints and aging-specific study designs.
  • Experience with proteomics, cross-species biomarker translation, or biomedical ontologies.
  • Familiarity with CRISPR and perturbation resources, or with pooled or arrayed screening.

About the Company

BioAge Labs

Clinical-stage biotech developing aging-targeted therapeutics

BioAge Labs develops therapies for age-related diseases by using a human-first discovery platform that maps human aging and translates those insights into a portfolio of drugs. Its approach starts from human aging profiles to identify drug targets and then creates medicines that prevent or treat diseases of aging, with the aim of extending healthy lifespan. The company operates in the clinical stage, developing longevity-focused therapeutics that can be sold to healthcare providers and patients as they progress through trials and gain approvals. What sets BioAge Labs apart is its focus on human aging biology as the starting point for drug development and its goal to address aging itself, not just individual diseases, providing a path to broader healthspan extension compared to traditional disease-focused approaches. The overarching goal is to deliver longevity medicine that delays or prevents age-related decline and improves healthspan for patients.

Company size
51-200
Company stage
Series D
Total funding
$293.9M
Headquarters
Emeryville, CA
Founded
2015

Recently Posted Jobs

Explore more opportunities at BioAge Labs

See more jobs